메뉴 건너뛰기




Volumn 21, Issue 10, 2015, Pages 2338-2347

Intracellular targeting of the oncogenic MUC1-C protein with a novel GO-203 nanoparticle formulation

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GO 203; MUCIN 1; NANOPARTICLE; TETRABLOCK POLYACETIC ACID POLYETHYLENE GLYCOL POLYPROPYLENE GLYCOL COPOLYMER; UNCLASSIFIED DRUG; (ARGININE)9-CYSTEINYL-GLUTAMINYL-CYSTEINYL-ARGINYL-ARGINYL-LYSYL-ASPARAGINE; MUC1 PROTEIN, HUMAN; NANOCAPSULE; PEPTIDE;

EID: 84941985471     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-3000     Document Type: Article
Times cited : (54)

References (44)
  • 1
    • 70450247207 scopus 로고    scopus 로고
    • Mucins in cancer: Function, prognosis and therapy
    • Kufe D. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer 2009;9:874-85.
    • (2009) Nat Rev Cancer , vol.9 , pp. 874-885
    • Kufe, D.1
  • 2
    • 69049089548 scopus 로고    scopus 로고
    • The prioritization of cancer antigens: A national cancer institute pilot project for the acceleration of translational research
    • Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009;15:5323-37.
    • (2009) Clin Cancer Res , vol.15 , pp. 5323-5337
    • Ma, C.1    Allison, J.P.2    Ferris, A.S.3    Finn, O.J.4    Hastings, B.M.5    Hecht, T.T.6
  • 3
    • 84901396865 scopus 로고    scopus 로고
    • Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells
    • Raina D, Uchida Y, Kharbanda A, Rajabi H, Panchamoorthy G, Jin C, et al. Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells. Oncogene 2013;33: 3422-31.
    • (2013) Oncogene , vol.33 , pp. 3422-3431
    • Raina, D.1    Uchida, Y.2    Kharbanda, A.3    Rajabi, H.4    Panchamoorthy, G.5    Jin, C.6
  • 4
    • 84908669769 scopus 로고    scopus 로고
    • Targeting the oncogenic MUC1-C protein inhibits mutant EGFR-mediated signaling and survival in non-small cell lung cancer cells
    • Kharbanda A, Rajabi H, Jin C, Tchaicha J, Kikuchi E, Wong K, et al. Targeting the oncogenic MUC1-C protein inhibits mutant EGFR-mediated signaling and survival in non-small cell lung cancer cells. Clin Cancer Res 2014; 20:5423-34.
    • (2014) Clin Cancer Res , vol.20 , pp. 5423-5434
    • Kharbanda, A.1    Rajabi, H.2    Jin, C.3    Tchaicha, J.4    Kikuchi, E.5    Wong, K.6
  • 5
    • 84874743726 scopus 로고    scopus 로고
    • MUC1-C oncoprotein as a target in breast cancer: Activation of signaling pathways and therapeutic approaches
    • Kufe D. MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene 2013;32: 1073-81.
    • (2013) Oncogene , vol.32 , pp. 1073-1081
    • Kufe, D.1
  • 6
    • 28544448610 scopus 로고    scopus 로고
    • MUC1 oncoprotein blocks GSK3b-mediated phosphorylation and degradation of b-catenin
    • Huang L, Chen D, Liu D, Yin L, Kharbanda S, Kufe D. MUC1 oncoprotein blocks GSK3b-mediated phosphorylation and degradation of b-catenin. Cancer Res 2005;65:10413-22.
    • (2005) Cancer Res , vol.65 , pp. 10413-10422
    • Huang, L.1    Chen, D.2    Liu, D.3    Yin, L.4    Kharbanda, S.5    Kufe, D.6
  • 7
    • 84858994452 scopus 로고    scopus 로고
    • MUC1-C oncoprotein induces TCF7L2 activation and promotes cyclin D1 expression in human breast cancer cells
    • Rajabi H, Ahmad R, Jin C, Kosugi M, Alam M, Joshi M, et al. MUC1-C oncoprotein induces TCF7L2 activation and promotes cyclin D1 expression in human breast cancer cells. J Biol Chem 2012;287: 10703-13.
    • (2012) J Biol Chem , vol.287 , pp. 10703-10713
    • Rajabi, H.1    Ahmad, R.2    Jin, C.3    Kosugi, M.4    Alam, M.5    Joshi, M.6
  • 8
    • 84898014554 scopus 로고    scopus 로고
    • MUC1-C oncoprotein activates the ZEB1/miR-200c regulatory loop and epithelial-mesenchymal transition
    • Rajabi H, Alam M, Takahashi H, Kharbanda A, Guha M, Ahmad R, et al. MUC1-C oncoprotein activates the ZEB1/miR-200c regulatory loop and epithelial-mesenchymal transition. Oncogene 2013;33:1680-9.
    • (2013) Oncogene , vol.33 , pp. 1680-1689
    • Rajabi, H.1    Alam, M.2    Takahashi, H.3    Kharbanda, A.4    Guha, M.5    Ahmad, R.6
  • 9
    • 84901235589 scopus 로고    scopus 로고
    • Targeting the MUC1-C oncoprotein inhibits self-renewal capacity of breast cancer cells
    • Alam M, Rajabi H, Ahmad R, Jin C, Kufe D. Targeting the MUC1-C oncoprotein inhibits self-renewal capacity of breast cancer cells. Oncotarget 2014;5:2622-34.
    • (2014) Oncotarget , vol.5 , pp. 2622-2634
    • Alam, M.1    Rajabi, H.2    Ahmad, R.3    Jin, C.4    Kufe, D.5
  • 10
    • 84910072604 scopus 로고    scopus 로고
    • MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells
    • Kharbanda A, Rajabi H, Jin C, Alam M, Wong K, Kufe D. MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells. Oncotarget 2014;5:8893-905.
    • (2014) Oncotarget , vol.5 , pp. 8893-8905
    • Kharbanda, A.1    Rajabi, H.2    Jin, C.3    Alam, M.4    Wong, K.5    Kufe, D.6
  • 11
    • 68149182606 scopus 로고    scopus 로고
    • Functional targeting of the MUC1 oncogene in human cancers
    • Kufe D. Functional targeting of the MUC1 oncogene in human cancers. Cancer Biol Ther 2009;8:1201-7.
    • (2009) Cancer Biol Ther , vol.8 , pp. 1201-1207
    • Kufe, D.1
  • 12
    • 67449127094 scopus 로고    scopus 로고
    • Direct targeting of the MUC1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells
    • RainaD, Ahmad R, Joshi M, Yin L,Wu Z, Kawano T, et al. Direct targeting of the MUC1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells. Cancer Res 2009;69:5133-41.
    • (2009) Cancer Res , vol.69 , pp. 5133-5141
    • Rainad Ahmad, R.1    Joshi, M.2    Yin Lwu, Z.3    Kawano, T.4
  • 13
    • 84860279784 scopus 로고    scopus 로고
    • Targeting cysteine-mediated dimerization of the MUC1-C oncoprotein in human cancer cells
    • Raina D, Ahmad R, Rajabi H, Panchamoorthy G, Kharbanda S, Kufe D. Targeting cysteine-mediated dimerization of the MUC1-C oncoprotein in human cancer cells. Int J Oncol 2012;40:1643-9.
    • (2012) Int J Oncol , vol.40 , pp. 1643-1649
    • Raina, D.1    Ahmad, R.2    Rajabi, H.3    Panchamoorthy, G.4    Kharbanda, S.5    Kufe, D.6
  • 16
    • 0032494119 scopus 로고    scopus 로고
    • Pharmacodynamic aspects of peptide administration biological response modifiers
    • Talmadge JE. Pharmacodynamic aspects of peptide administration biological response modifiers. Adv Drug Deliv Rev 1998;33:241-52.
    • (1998) Adv Drug Deliv Rev , vol.33 , pp. 241-252
    • Talmadge, J.E.1
  • 19
    • 76649141217 scopus 로고    scopus 로고
    • Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes
    • Sarafraz-Yazdi E, Bowne WB, Adler V, Sookraj KA, Wu V, Shteyler V, et al. Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes. Proc Natl Acad Sci U S A 2010;107:1918-23.
    • (2011) Proc Natl Acad Sci U S A , vol.107 , pp. 1918-1923
    • Sarafraz-Yazdi, E.1    Bowne, W.B.2    Adler, V.3    Sookraj, K.A.4    Wu, V.5    Shteyler, V.6
  • 20
    • 84899509680 scopus 로고    scopus 로고
    • ASpecific STAT3-binding peptide exerts antiproliferative effects and antitumor activity by inhibiting STAT3 phosphorylation and signaling
    • KimD, Lee IH,Kim S, Choi M, KimH, Ahn S, et al.ASpecific STAT3-binding peptide exerts antiproliferative effects and antitumor activity by inhibiting STAT3 phosphorylation and signaling. Cancer Res 2014;74:1-8.
    • (2014) Cancer Res , vol.74 , pp. 1-8
    • Kimd Lee Ihkim, S.1    Choi, M.2    Kim, H.3    Ahn, S.4
  • 21
    • 84897387919 scopus 로고    scopus 로고
    • A novel peptide that inhibits E2F transcription and regresses prostate tumor xenografts
    • Xie X, Bansal N, Shaik T, Kerrigan J, Minko T, Garbuzenko O, et al. A novel peptide that inhibits E2F transcription and regresses prostate tumor xenografts. Oncotarget 2014;5:901-7.
    • (2014) Oncotarget , vol.5 , pp. 901-907
    • Xie, X.1    Bansal, N.2    Shaik, T.3    Kerrigan, J.4    Minko, T.5    Garbuzenko, O.6
  • 22
    • 84869507166 scopus 로고    scopus 로고
    • Finding the optimal balance: Challenges of improving conventional cancer chemotherapy using suitable combinations with nano-sized drug delivery systems
    • Kratz F, Warnecke A. Finding the optimal balance: challenges of improving conventional cancer chemotherapy using suitable combinations with nano-sized drug delivery systems. J Control Release 2012;164: 221-35.
    • (2012) J Control Release , vol.164 , pp. 221-235
    • Kratz, F.1    Warnecke, A.2
  • 23
    • 84868256944 scopus 로고    scopus 로고
    • Overcoming limitations in nanoparticle drug delivery: Triggered, intravascular release to improve drug penetration into tumors
    • Manzoor AA, Lindner LH, Landon CD, Park JY, Simnick AJ, Dreher MR, et al. Overcoming limitations in nanoparticle drug delivery: Triggered, intravascular release to improve drug penetration into tumors. Cancer Res 2012;72:5566-75.
    • (2012) Cancer Res , vol.72 , pp. 5566-5575
    • Manzoor, A.A.1    Lindner, L.H.2    Landon, C.D.3    Park, J.Y.4    Simnick, A.J.5    Dreher, M.R.6
  • 24
    • 84858652159 scopus 로고    scopus 로고
    • Targeted polymeric therapeutic nanoparticles: Design, development and clinical translation
    • Kamaly N, Xiao Z, Valencia PM, Radovic-Moreno AF, Farokhzad OC. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev 2012;41:2971-3010.
    • (2012) Chem Soc Rev , vol.41 , pp. 2971-3010
    • Kamaly, N.1    Xiao, Z.2    Valencia, P.M.3    Radovic-Moreno, A.F.4    Farokhzad, O.C.5
  • 25
    • 84902188616 scopus 로고    scopus 로고
    • Novel polymeric nanoparticles for intracellular delivery of peptide cargos: Antitumor efficacy of the BCL-2 conversion peptide NuBCP-9
    • Kumar M, Gupta D, Singh G, Sharma S, BhattM, Prashant CK, et al. Novel polymeric nanoparticles for intracellular delivery of peptide cargos: antitumor efficacy of the BCL-2 conversion peptide NuBCP-9. Cancer Res 2014;74:1-11.
    • (2014) Cancer Res , vol.74 , pp. 1-11
    • Kumar, M.1    Gupta, D.2    Singh, G.3    Sharma, S.4    Bhattm Prashant, C.K.5
  • 26
    • 67249139762 scopus 로고    scopus 로고
    • Cationic liposomes loaded with proapoptotic peptide D-(KLAKLAK)(2) and Bcl-2 antisense oligodeoxynucleotide G3139 for enhanced anticancer therapy
    • Ko YT, Falcao C, Torchilin VP. Cationic liposomes loaded with proapoptotic peptide D-(KLAKLAK)(2) and Bcl-2 antisense oligodeoxynucleotide G3139 for enhanced anticancer therapy. Mol Pharm 2009; 6:971-7.
    • (2009) Mol Pharm , vol.6 , pp. 971-977
    • Ko, Y.T.1    Falcao, C.2    Torchilin, V.P.3
  • 27
    • 70349220917 scopus 로고    scopus 로고
    • Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing cell growth
    • Soman NR, Baldwin SL, Hu G, Marsh JN, Lanza GM, Heuser J, et al. Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing cell growth. J Clin Invest 2009;119:2830-42.
    • (2009) J Clin Invest , vol.119 , pp. 2830-2842
    • Soman, N.R.1    Baldwin, S.L.2    Hu, G.3    Marsh, J.N.4    Lanza, G.M.5    Heuser, J.6
  • 29
    • 84855766402 scopus 로고    scopus 로고
    • Nanoparticle delivery of a peptide targeting EGFR signaling
    • Kim SK, Huang L. Nanoparticle delivery of a peptide targeting EGFR signaling. J Control Release 2012;157:279-86.
    • (2012) J Control Release , vol.157 , pp. 279-286
    • Kim, S.K.1    Huang, L.2
  • 30
    • 83455238243 scopus 로고    scopus 로고
    • A monoclonal antibody against the oncogenic mucin 1 cytoplasmic domain
    • Panchamoorthy G, Rehan H, Kharbanda A, Ahmad R, Kufe D. A monoclonal antibody against the oncogenic mucin 1 cytoplasmic domain. Hybridoma 2011;30:531-5.
    • (2011) Hybridoma , vol.30 , pp. 531-535
    • Panchamoorthy, G.1    Rehan, H.2    Kharbanda, A.3    Ahmad, R.4    Kufe, D.5
  • 32
    • 2542559832 scopus 로고    scopus 로고
    • Phase i and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies
    • Kim TY, Kim DW, Chung JY, Shin SG, Kim SC, Heo DS, et al. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res 2004;10:3708-16.
    • (2004) Clin Cancer Res , vol.10 , pp. 3708-3716
    • Kim, T.Y.1    Kim, D.W.2    Chung, J.Y.3    Shin, S.G.4    Kim, S.C.5    Heo, D.S.6
  • 33
    • 84873481897 scopus 로고    scopus 로고
    • Inhibition of the MUC1-C oncoprotein is synergistic with cytotoxic agents in treatment of breast cancer cells
    • Uchida Y, Raina D, Kharbanda S, Kufe D. Inhibition of the MUC1-C oncoprotein is synergistic with cytotoxic agents in treatment of breast cancer cells. Cancer Biol Ther 2013;14:127-34.
    • (2013) Cancer Biol Ther , vol.14 , pp. 127-134
    • Uchida, Y.1    Raina, D.2    Kharbanda, S.3    Kufe, D.4
  • 34
    • 84880534957 scopus 로고    scopus 로고
    • MUC1-C oncoprotein induces tamoxifen resistance in human breast cancer
    • Kharbanda A, Rajabi H, Jin C, Raina D, Kufe D. MUC1-C oncoprotein induces tamoxifen resistance in human breast cancer. Mol Cancer Res 2013;11:714-23.
    • (2013) Mol Cancer Res , vol.11 , pp. 714-723
    • Kharbanda, A.1    Rajabi, H.2    Jin, C.3    Raina, D.4    Kufe, D.5
  • 35
    • 84856072436 scopus 로고    scopus 로고
    • Inhibition of the MUC1-C oncoprotein induces multiple myeloma cell death by downregulating TIGAR expression and depleting NADPH
    • Yin L, Kosugi M, Kufe D. Inhibition of the MUC1-C oncoprotein induces multiple myeloma cell death by downregulating TIGAR expression and depleting NADPH. Blood 2012;119:810-6.
    • (2012) Blood , vol.119 , pp. 810-816
    • Yin, L.1    Kosugi, M.2    Kufe, D.3
  • 36
    • 33745918951 scopus 로고    scopus 로고
    • TIGAR, a p53-inducible regulator of glycolysis and apoptosis
    • Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006;126:107-20.
    • (2006) Cell , vol.126 , pp. 107-120
    • Bensaad, K.1    Tsuruta, A.2    Ma, S.3    Vidal, M.N.4    Nakano, K.5    Bartrons, R.6
  • 37
    • 55349095456 scopus 로고    scopus 로고
    • Cellular senescence: Molecular mechanisms, in vivo significance, and redox considerations
    • Muller M. Cellular senescence: molecular mechanisms, in vivo significance, and redox considerations. Antioxid Redox Signal 2009;11: 59-98.
    • (2009) Antioxid Redox Signal , vol.11 , pp. 59-98
    • Muller, M.1
  • 39
    • 0037948854 scopus 로고    scopus 로고
    • Vitro propagation and transcriptional profiling of human mammary stem/progenitor cells
    • Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ, et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 2003;17: 1253-70.
    • (2003) Genes Dev , vol.17 , pp. 1253-1270
    • Dontu, G.1    Abdallah, W.M.2    Foley, J.M.3    Jackson, K.W.4    Clarke, M.F.5    Kawamura, M.J.6
  • 40
    • 34548569038 scopus 로고    scopus 로고
    • Enrichment of a population of mammary gland cells that form mammospheres and have in vivo repopulating activity
    • Liao MJ, Zhang CC, Zhou B, Zimonjic DB, Mani SA, Kaba M, et al. Enrichment of a population of mammary gland cells that form mammospheres and have in vivo repopulating activity. Cancer Res 2007; 67:8131-8.
    • (2007) Cancer Res , vol.67 , pp. 8131-8138
    • Liao, M.J.1    Zhang, C.C.2    Zhou, B.3    Zimonjic, D.B.4    Mani, S.A.5    Kaba, M.6
  • 41
    • 70349388055 scopus 로고    scopus 로고
    • Therapeutic peptides for cancer therapy Part i -peptide inhibitors of signal transduction cascades
    • Bidwell GL 3rd, Raucher D. Therapeutic peptides for cancer therapy. Part I -peptide inhibitors of signal transduction cascades. Expert Opin Drug Deliv 2009;6:1033-47.
    • (2009) Expert Opin Drug Deliv , vol.6 , pp. 1033-1047
    • Bidwell, G.L.1    Raucher, D.2
  • 42
    • 70349383205 scopus 로고    scopus 로고
    • Therapeutic peptides for cancer therapy Part II -cell cycle inhibitory peptides and apoptosis-inducing peptides
    • Raucher D, Moktan S, Massodi I, Bidwell GL3rd. Therapeutic peptides for cancer therapy. Part II -cell cycle inhibitory peptides and apoptosis-inducing peptides. Expert Opin Drug Deliv 2009;6: 1049-64.
    • (2009) Expert Opin Drug Deliv , vol.6 , pp. 1049-1064
    • Raucher, D.1    Moktan, S.2    Massodi, I.3    Bidwell, G.L.4
  • 43
    • 84900441753 scopus 로고    scopus 로고
    • Targeting the MUC1-C oncoprotein is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated multiple myeloma cell death
    • Yin L, Kufe T, Avigan D, Kufe D. Targeting the MUC1-C oncoprotein is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated multiple myeloma cell death. Blood 2014;123:2997-3006.
    • (2014) Blood , vol.123 , pp. 2997-3006
    • Yin, L.1    Kufe, T.2    Avigan, D.3    Kufe, D.4
  • 44
    • 77949849959 scopus 로고    scopus 로고
    • Blends of oppositely charged PEG-PPG-PEG copolymers displaying improved physical thermogelling properties
    • Lee SY, Lee Y, Chae SU, Park TG, Ahn C. Blends of oppositely charged PEG-PPG-PEG copolymers displaying improved physical thermogelling properties. Macromol Chem Phy 2010;211:692-7.
    • (2011) Macromol Chem Phy , vol.211 , pp. 692-697
    • Lee, S.Y.1    Lee, Y.2    Chae, S.U.3    Park, T.G.4    Ahn, C.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.